Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Experimental disease models for the assessment of meningococcal vaccines.

Gorringe AR, Reddin KM, Funnell SG, Johansson L, Rytkönen A, Jonsson AB.

Vaccine. 2005 Mar 18;23(17-18):2214-7.

PMID:
15755598
2.

Rapid characterization of outer-membrane proteins in Neisseria lactamica by SELDI-TOF-MS (surface-enhanced laser desorption ionization-time-of-flight MS) for use in a meningococcal vaccine.

Mukhopadhyay TK, Halliwell D, O'Dwyer C, Shamlou PA, Levy MS, Allison N, Gorringe A, Reddin KM.

Biotechnol Appl Biochem. 2005 Apr;41(Pt 2):175-82.

PMID:
15315478
3.

Preparation of polysaccharide-conjugate vaccines.

Peeters CC, Lagerman PR, de Weers O, Oomen LA, Hoogerhout P, Beurret M, Poolman JT, Reddin KM.

Methods Mol Med. 2003;87:153-74. No abstract available.

PMID:
12958455
4.

Neisseria lactamica protects against experimental meningococcal infection.

Oliver KJ, Reddin KM, Bracegirdle P, Hudson MJ, Borrow R, Feavers IM, Robinson A, Cartwright K, Gorringe AR.

Infect Immun. 2002 Jul;70(7):3621-6.

5.

Bordetella pertussis fimbriae are effective carrier proteins in Neisseria meningitidis serogroup C conjugate vaccines.

Reddin KM, Crowley-Luke A, Clark SO, Vincent PJ, Gorringe AR, Hudson MJ, Robinson A.

FEMS Immunol Med Microbiol. 2001 Aug;31(2):153-62.

6.

Animal models for meningococcal disease.

Gorringe AR, Reddin KM, Voet P, Poolman JT.

Methods Mol Med. 2001;66:241-54. doi: 10.1385/1-59259-148-5:241.

PMID:
21336759
7.

Human opsonins induced during meningococcal disease recognize transferrin binding protein complexes.

Lehmann AK, Gorringe AR, Reddin KM, West K, Smith I, Halstensen A.

Infect Immun. 1999 Dec;67(12):6526-32.

8.

Comparison of the immunological and protective responses elicited by microencapsulated formulations of the F1 antigen from Yersinia pestis.

Reddin KM, Easterbrook TJ, Eley SM, Russell P, Mobsby VA, Jones DH, Farrar GH, Williamson ED, Robinson A.

Vaccine. 1998 May;16(8):761-7.

PMID:
9627932
9.

Periplasmic superoxide dismutase in meningococcal pathogenicity.

Wilks KE, Dunn KL, Farrant JL, Reddin KM, Gorringe AR, Langford PR, Kroll JS.

Infect Immun. 1998 Jan;66(1):213-7.

10.

A new improved sub-unit vaccine for plague: the basis of protection.

Williamson ED, Eley SM, Griffin KF, Green M, Russell P, Leary SE, Oyston PC, Easterbrook T, Reddin KM, Robinson A, et al.

FEMS Immunol Med Microbiol. 1995 Dec;12(3-4):223-30.

PMID:
8745007
11.

Large-scale purification of the F1 antigen of Yersinia pestis.

Reddin KM, Easterbrook TJ, Robinson A, Williamson D, Rhind-tutt R.

Contrib Microbiol Immunol. 1995;13:329-30. No abstract available.

PMID:
8833865

Supplemental Content

Loading ...
Support Center